Chairman of the Board - Eckard Weber, M.D.
Dr. Weber joined Domain in 2001 as a partner where he specializes in creating companies around promising new pharmaceutical products. He has been founding CEO of multiple biopharmaceutical companies in the Domain portfolio including Acea Pharmaceuticals, Ascenta Therapeutics, Calixa Therapeutics, Cytovia, Domain Antibacterial Acquisition Corporation, NovaCardia, Novacea, Novalar Pharmaceuticals, Ocera Therapeutics, Orexigen Therapeutics, Sonexa Therapeutics, Syndax Pharmaceuticals, Tobira Therapeutics and Tragara Pharmaceuticals. He currently serves as interim CEO of Calixa Therapeutics and Sonexa Therapeutics, two seed-stage biopharmaceutical companies. He is Chairman of the Board at Ascenta Therapeutics, Calixa Therapeutics, Ocera Therapeutics, Orexigen Therapeutics, Sequel Pharmaceuticals, and Tobira Therapeutics. He was Chairman of Peninsula Pharmaceuticals until the company was sold to Johnson & Johnson in 2005, Chairman of Cerexa until the company was sold to Forest Laboratories in January 2007, Chairman of NovaCardia until the company was sold to Merck in September of 2007, and a Board member of Conforma Therapeutics and Cabrellis Pharmaceuticals until they were sold to Biogen-IDEC and Pharmion, respectively.  Until 1995, Dr. Weber was a tenured Professor of Pharmacology at the University of California at Irvine. He has over 20 years of drug discovery and development experience and has been a consultant to biotechnology and pharmaceutical companies. He is the inventor or co-inventor of over 40 patents and patent applications, and he has published over 130 papers in scientific periodicals.

Brian Halak, Ph.D.
Brian Halak is a principal with Domain Associates. Previously, Dr. Halak worked for Advanced Technology Ventures, a venture capital firm, and for Wilkerson Group, a management consulting firm devoted exclusively to the medical industry. In this capacity, he developed strategy for leading firms in the pharmaceutical, biotechnology and medical device industries. Dr. Halak received a doctorate in immunology from Thomas Jefferson University and a Bachelor of Science degree in engineering from the University of Pennsylvania. He has also published and presented on the topic of tumor immunology. Halak serves on the Investment Advisory Council for Ben Franklin Technology Partners and BioAdvance, both of which are Philadelphia seed-stage investment groups.

Patrick Heron
Mr. Heron is a General Partner with Frazier Healthcare Ventures., which focuses on biotechnology and growth equity opportunities. Mr. Heron joined Frazier Healthcare in 1999 and founded QuatRx Pharmaceuticals, an in-licensor of early-stage clinical development compounds, with its core management team in late 2000. He also led the opening of Frazier Healthcare's Palo Alto office in the summer of 2003. Mr. Heron currently serves on the boards of Avera Pharmaceuticals, Cerexa, Chimerix, Genospectra, Informed Medical Communications, QuatRx Pharmaceuticals and Trubion Pharmaceuticals. Prior to joining Frazier Healthcare, Mr. Heron helped develop McKinsey & Co.'s West Coast biotechnology consulting practice after starting his career working with large pharmaceutical clients on the East Coast. His projects included corporate strategy, M&A, product launch, sales force optimization, corporate partnering and research prioritization. Before joining McKinsey, Mr. Heron also worked with Massachusetts General Hospital in evaluating spin-off opportunities and with Cetus Corporation. He was a Morehead Scholar at the University of North Carolina at Chapel Hill and holds an M.B.A. from Harvard Business School.

Daniel K. Turner III
Mr. Turner has 20 years of experience as an entrepreneur, operating manager and venture capitalist. He founded Montreux and has been a General Partner/Managing Member since 1993. Immediately prior to founding Montreux, Mr. Turner was a Principal in the Turnaround Group for Berkeley International. In addition, he was the founding Chief Financial Officer of Oclassen Pharmaceuticals, a specialty pharmaceutical company focused in dermatology, which merged with Watson Pharmaceuticals (NYSE: WPI) in 1997. Mr. Turner started his career with Price Waterhouse in the high technology group. He holds a B.S. from California State University, Sacramento (magna cum laude) and attended the M.B.A. program at the Haas School of Business at the University of California, Berkeley, where he has established the Turner Fellowship. Mr. Turner is also a member of the board of directors of NeurogesX (NASDAQ: NGSX), OREXIGEN (NASDAQ: OREX), Renal CarePartners, Somaxon (NASDAQ: SOMX), Transcept Pharmaceuticals and Tobira Therapeutics. He previously served as Montreux’s representative to the board of directors of Cerexa (sold to Forest Laboratories, 2007), NovaCardia (sold to Merck, 2007), and Peninsula Pharmaceuticals (sold to Johnson & Johnson, 2005). In addition to his activities at Montreux, Mr. Turner is a member of the Board of Trustees at Woodside Priory School and is a Certified Public Accountant.

Michael J. Kamdar
Michael J. Kamdar is a founder of VentiRx Pharmaceuticals, and currently serves as Executive Vice President, Chief Business Officer and is a member of the Board of Directors. Prior to VentiRx, Mr. Kamdar served as Senior Vice President, Corporate Development and Finance at Anadys Pharmaceuticals. During this time, Mr. Kamdar led a $570M transaction with Novartis that focused on the company's lead Toll-like receptor-7 (TLR7) program. This transaction was awarded "The Most Creative and Significant Deal of 2005" at the 18th Annual Biotech CEO Meeting. In addition, Mr. Kamdar played an instrumental role in the company's initial public offering in March 2004. Prior to this, Mr. Kamdar served as Anadys' Vice President, Corporate Development and Strategy, with responsibility for business development, as well as investor relations, corporate communications, and global strategic planning.

From 2000 to 2001, Mr. Kamdar was Senior Director, Business Development at Agouron Pharmaceuticals, a Pfizer Company. Mr. Kamdar was at Agouron from 1994 through 2001, which was acquired by Warner-Lambert in 1999. Mr. Kamdar held various business development positions and responsibilities at Agouron that culminated with his assumption of global responsibility for corporate partnering, in-licensing, technology acquisition, and strategic alliance efforts in the anti-infective, oncology, and ophthalmology therapeutic areas.

Prior to Agouron, Mr. Kamdar held various product management and new product planning positions for Hybritech, Inc., an Eli Lilly Company, and Centocor, Inc. He received his B.S. in Biology from St. Joseph's University and his M.B.A. from Villanova University.

Laurent Fischer, M.D.
Dr. Fischer is the Co-Founder, President and Chief Executive Officer of Ocera Therapeutics, a San Diego based biopharmaceutical company developing novel compounds for liver and gastro-intestinal diseases. He brings over 17 years of drug development and commercialization experience in the biopharmaceutical industry. He has been involved in and managed four healthcare companies and held senior management positions at DuPont-Merck, DuPont Pharmaceuticals, and Hoffmann-La Roche. Dr Fischer was responsible for the launch of Invirase®, the first protease inhibitor, and Sustiva® the first once-daily anti-HIV now part of the triple combination therapy Atripla®. Dr. Fischer serves on the board of directors of Panacos and is Chair of the board of directors of the AIDS Healthcare Foundation, a foundation providing treatment and AIDS services to 100,000 people living with HIV and AIDS in 22 countries.

Carol L. Brosgart, MD
Carol L. Brosgart, MD, retired from Gilead Sciences, Inc., July 1, 2009 where she was Vice President, Public Health and Policy. Carol joined Gilead as Director, Clinical Research in 1998 and was promoted to Vice President, Clinical Research in 2001. During her tenure leading the antiviral clinical drug development programs, Viread® (tenofovir disoproxil fumarate), for the treatment of HIV (2001) and Hepsera® (adefovir dipivoxil), for the treatment of chronic hepatitis B (2002) were licensed. In 2005, Dr. Brosgart started a new department at Gilead, focusing on public health and policy. Her domestic and global efforts have focused on establishing HIV testing as part of routine health care; increasing awareness, screening and linkage to care for chronic hepatitis B and C; seasonal and pandemic influenza planning; the elimination of racial and ethnic disparities in health care; and, improved access to care and chronic disease management of infectious diseases of public health importance.

Prior to Gilead, Dr. Brosgart spent over 20 years in clinical care, research and teaching as the Medical Director of the East Bay AIDS Center (1987-1998) at Alta Bates Medical Center and the Central Health Center (1978-1987) of the Alameda County Health Care Services Agency. Starting in 1981, she was one of the first physicians in the U.S. to identify and treat HIV patients. She directed NIH collaborative research trials as a member of the leadership of the Community Programs for Clinical Research on AIDS (CPCRA) and contributed to the development of antiretrovirals for HIV and on agents for the prophylaxis and treatment of opportunistic complications of HIV. Serving in an advisory capacity to the State of California, NIH, CDC, and the AHCPR/HRSA, she has contributed to public health policy for HIV and other communicable diseases. She joined the National HBV Task Force of the Office of Minority Health in 2007. Dr. Brosgart is a member of the clinical faculty of the University of California, San Francisco (UCSF) and the Joint Medical Program at the University of California, Berkeley (UCB). During her service in both the public and private sectors, she has published extensively in the areas of infectious diseases, focusing on antiviral therapy for CMV, HIV, and HBV. In 2007, Dr. Brosgart was appointed to the Board of Directors of Juvaris BioTherapeutics, Inc, a privately held biotechnology company, developing novel vaccines for infectious diseases and oncology and to the Health Management Institute of the National Association of Managed Care Physicians. She was elected to the Board of Directors of the National Hispanic Medical Association and the San Francisco AIDS Foundation in 2008. In 2009, she joined the Board of Directors of Tobira Therapeutics, Inc. and the Hepatitis B Foundation Medical and Scientific Advisory Board.

Dr. Brosgart completed an undergraduate degree at the UCB in 1973 with an independent major in community medicine. Her medical degree was completed at the UCSF in 1977. Dr. Brosgart trained in pediatrics at UCSF and completed an additional residency in preventive medicine at the California State Department of Public Health and the UCB.

James Sapirstein, RPh, MBA
Refer to Management Page